ISRG Stock Analysis: Intuitive Surgical | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 158.537m USD | 12M Return: -18.5% | US46120E6023 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 947M
EPS Trend: 99.9%
Qual. Beats: 6
Rev. Trend: 99.8%
Qual. Beats: 9
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Intuitive Surgical, Inc. (NASDAQ: ISRG), headquartered in Sunnyvale, California, develops, manufactures, and markets products that enable physicians and healthcare providers to deliver minimally invasive care across the United States and international markets. The company was incorporated in 1995 and went public in June 2000. With a market capitalization of approximately $142.7 billion, ISRG is classified as a large-cap stock within the Health Care Equipment sub-industry of the broader Health Care sector.
The companys flagship offering is the da Vinci Surgical System, a multi-port robotic platform that allows surgeons to perform minimally invasive procedures. It also offers the Ion endoluminal system, which extends its commercial reach into diagnostic procedures by enabling minimally invasive lung biopsies. These platforms are complemented by a suite of stapling, energy, and core instrumentation, along with progressive learning programs to support surgeon training and adoption.
Beyond hardware, Intuitive Surgical generates recurring revenue through an extensive services and support infrastructure, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring. The company also provides integrated digital capabilities that deliver connected, data-driven insights to hospital customers. Its products are sold primarily through direct sales organizations composed of dedicated capital and clinical sales teams, a model that supports close alignment with the hospitals and surgical centers that deploy its systems.
- da Vinci procedure volumes lift recurring instrument and accessory revenue
- Ion endoluminal system adoption expands addressable diagnostic market
- Medtronic Hugo and J&J Ottava intensify robotic surgery competition
| Net Income: 2.96b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 6.86 > 1.0 |
| NWC/Revenue: 50.92% < 20% (prev 69.93%; Δ -19.02% < -1%) |
| CFO/TA 0.21 > 3% & CFO 4.09b > Net Income 2.96b |
| Net Debt (-3.65b) to EBITDA (4.78b): -0.76 < 3 |
| Current Ratio: 3.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (351.6m) vs 12m ago -2.82% < -2% |
| Gross Margin: 67.19% > 18% (prev 66.38%; Δ 0.81% > 0.5%) |
| Asset Turnover: 59.83% > 50% (prev 49.67%; Δ 10.16% > 0%) |
| Interest Coverage Ratio: 13.31 > 6 (EBIT TTM 3.91b / Interest Expense TTM 293.9m) |
| A: 0.30 (Total Current Assets 8.43b - Total Current Liabilities 2.53b) / Total Assets 19.3b |
| B: 0.23 (Retained Earnings 4.53b / Total Assets 19.3b) |
| C: 0.20 (EBIT TTM 3.91b / Avg Total Assets 19.4b) |
| D: 4.95 (Book Value of Equity 16.0b / Total Liabilities 3.23b) |
| Altman-Z'' = 9.31 = AAA |
| DSRI: 1.03 (Receivables 1.72b/1.38b, Revenue 11.6b/9.61b) |
| GMI: 0.99 (GM 66.38% / 67.19%) |
| AQI: 0.92 (AQ_t 0.27 / AQ_t-1 0.29) |
| SGI: 1.20 (Revenue 11.6b / 9.61b) |
| TATA: -0.06 (NI 2.96b - CFO 4.09b) / TA 19.3b) |
| Beneish M = -2.91 (Cap -4..+1) = A |
As of November 01, 2026, the stock is trading at USD 432.01 with a total of 3,481,627 shares traded. Over the past week, the price has changed by -4.48%, over one month by +4.81%, over three months by +22.39% and over the past year by -18.49%.
Current recommended Stop Loss: 417.10 (which is 3.5% or 1.2 ATR below the current price).
Intuitive Surgical has received a consensus analysts rating of 4.24. Therefore, it is recommended to buy ISRG.
- StrongBuy: 18
- Buy: 8
- Hold: 7
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 482.6 | 11.7% |
P/E Trailing = 54.2636
P/E Forward = 36.63
P/S = 13.693
P/B = 9.8159
P/EG = 2.0572
Revenue TTM = 11.6b USD
EBIT TTM = 3.91b USD
EBITDA TTM = 4.78b USD
Long Term Debt = unknown (none)
Short Term Debt = 39.0m USD (from shortTermDebt, last fiscal year)
Debt = 389.8m USD (from shortLongTermDebtTotal, last fiscal year) + Leases 87.0m
Net Debt = -3.65b USD (calculated: Debt 389.8m - CCE 4.04b)
Enterprise Value = 155b USD (159b + Debt 389.8m - CCE 4.04b)
Interest Coverage Ratio = 13.31 (Ebit TTM 3.91b / Interest Expense TTM 293.9m)
EV/FCF = 43.05x (Enterprise Value 155b / FCF TTM 3.60b)
FCF Yield = 2.32% (FCF TTM 3.60b / Enterprise Value 155b)
FCF Margin = 31.08% (FCF TTM 3.60b / Revenue TTM 11.6b)
Net Margin = 25.54% (Net Income TTM 2.96b / Revenue TTM 11.6b)
Gross Margin = 67.19% ((Revenue TTM 11.6b - Cost of Revenue TTM 3.80b) / Revenue TTM)
Gross Margin QoQ = 68.37% (prev 67.78%)
Tobins Q-Ratio = 8.00 (Enterprise Value 155b / Total Assets 19.3b)
Interest Expense / Debt = 75.40% (Interest Expense 293.9m / Debt 389.8m)
Taxrate = 17.85% (645.9m / 3.62b)
NOPAT = 3.21b (EBIT 3.91b * (1 - 17.85%))
Current Ratio = 3.33 (Total Current Assets 8.43b / Total Current Liabilities 2.53b)
Debt / Equity = 0.02 (Debt 389.8m / totalStockholderEquity, last quarter 16.0b)
Debt / EBITDA = -0.76 (Net Debt -3.65b / EBITDA 4.78b)
Debt / FCF = -1.02 (Net Debt -3.65b / FCF TTM 3.60b)
Total Stockholder Equity = 17.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.28% (Net Income 2.96b / Total Assets 19.3b)
RoE = 17.03% (Net Income TTM 2.96b / Total Stockholder Equity 17.4b)
RoCE = 23.27% (EBIT 3.91b / Capital Employed (Total Assets 19.3b - Current Liab 2.53b))
RoIC = 19.75% (NOPAT 3.21b / Invested Capital 16.3b)
WACC = 8.79% (E(159b)/V(159b) * Re(8.81%) + (debt cost/tax rate unavailable))
Discount Rate = 8.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -71.95 | Cagr: -1.17%
[DCF] Terminal Value 76.56% ; FCFF base≈3.07b ; Y1≈3.52b ; Y5≈5.17b
[DCF] Fair Price = 215.0 (EV 72.3b - Net Debt -3.65b = Equity 76.0b / Shares 353.3m; r=8.79% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.90 | EPS CAGR: 26.40% | SUE: 4.0 | # QB: 6
Revenue Correlation: 99.85 | Revenue CAGR: 20.08% | SUE: 3.12 | # QB: 9
EPS current Quarter (2027-03-31): EPS=2.85 | Chg30d=+2.01% | Revisions=-25% | Analysts=21
EPS current Year (2026-12-31): EPS=11.25 | Chg30d=+4.26% | Revisions=-25% | GrowthEPS=+26.0% | GrowthRev=+18.5%
EPS next Year (2027-12-31): EPS=12.45 | Chg30d=+2.98% | Revisions=+0% | GrowthEPS=+10.6% | GrowthRev=+11.9%
[Analyst] Revisions Ratio: -29% (up=1, down=3)